From Diagnosis to Family Risk: Implementing Germline Genetic Testing in Prostate Cancer

Watch our recent webinar focused on the critical role of germline genetic testing in prostate cancer care, and how it impacts both patients and their families. This webinar will explore the latest clinical evidence and expert guidance on identifying hereditary risk, integrating genetic testing into urology workflows, and using results to inform treatment decisions and family risk assessment. The Germline Genetic Testing Clinical Pathway emphasizes the importance of identifying inherited cancer risk as a foundational component of prostate cancer care. Germline genetic testing can uncover hereditary mutations that influence cancer risk, disease aggressiveness, and long-term management, while also revealing potential implications for family members who may be at increased risk. By integrating germline genetic testing into routine urology practice, clinicians can enable earlier risk awareness, support informed clinical decision-making, and guide appropriate genetic counseling and screening for relatives—helping to protect not just the patient, but generations beyond.

• The clinical importance of germline genetic testing in prostate cancer and how inherited mutations can affect diagnosis, prognosis, and long-term management
• How to identify appropriate prostate cancer patients for germline genetic testing and incorporate testing into routine urology workflows
• Ways germline genetic test results can inform family risk assessment, guide genetic counseling, and support proactive screening for at-risk relatives